CD19 and acute lymphoblastic leukemia: Blinatumomab, a CD19/CD3-bispecific bispecific T cell engager (BiTE®) antibody construct, is the first molecule of this class approved in the U.S. and E.U. It induces durable complete remission in patients with minimal residual disease and r/r B-ALL [2, 3], and was shown to be effective in patients with non-Hodgkin’s lymphoma [4].